Corrigendum to “Nutritional status and growth hormone regulate insulin-like growth factor binding protein (igfbp) transcripts in Mozambique tilapia” [Gen. Comp. Endocrinol. 207 (2014) 66–73]

Abstract Although insulin-like growth factor-binding protein-2 (IGFBP-2) is an abundant IGFBP in fetal and postnatal plasma, its regulation is not yet clearly understood. To address this question in sheep, we purified ovine IGFBP-2 and developed a homologous radioimmunoassay. We have studied its ontogenesis and measured serum concentrations of ovine IGFBP-2 after bovine growth hormone (bGH), ovine placental lactogen (oPL) and IGF-I treatment. Concentrations of IGFBP-2 were high at 125 days of gestation (550 ± 15 μg/l) but fell after birth P<0·05) and plateaued after 1 year of age (340 ± 20 μg/l). In lactating ewes, bGH treatment for 7 days significantly reduced (21%; P<0·05) IGFBP-2 relative to the saline-treated group. Similarly, in neonatal lambs, bGH treatment from day 3 to day 23 of life reduced (P<0·05) IGFBP-2 by 23% relative to the saline-treated group. oPL had no effect on serum levels of IGFBP-2 in the ewe or the neonatal lamb. In well-fed yearling lambs, treatment with IGF-I reduced IGFBP-2 values by 27% (P<0·05) relative to control animals. In yearling lambs, reduced nutrition increased plasma IGFBP-2 (41%; P<0·05). However this increase was abolished by IGF-I treatment. The changes in plasma levels of IGFBP-2 were positively related to changes in IGF-II while there was a negative relationship between circulating IGF-I and IGFBP-2 such that both IGF-I and IGF-II may play a role in the regulation of IGFBP-2 in serum. Journal of Endocrinology (1995) 144, 75–82

Download Full-text

Time dependent impact of perinatal hypoxia on growth hormone, insulin-like growth factor 1 and insulin-like growth factor binding protein-3

Metabolic Brain Disease ◽

10.1007/s11011-016-9816-z ◽

2016 ◽

Vol 31 (4) ◽

pp. 827-835 ◽

Cited By ~ 9

Author(s):

Ömer Kartal ◽

Seçil Aydınöz ◽

Ayşe Tuğba Kartal ◽

Taha Kelestemur ◽

Ahmet Burak Caglayan ◽

...

Keyword(s):

Growth Hormone ◽

Growth Factor ◽

Binding Protein ◽

Time Dependent ◽

Insulin Like Growth Factor ◽

Perinatal Hypoxia ◽

Factor Binding

Download Full-text

Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone–stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels

Fertility and Sterility ◽

10.1016/s0015-0282(98)00432-4 ◽

1999 ◽

Vol 71 (2) ◽

pp. 261-267 ◽

Cited By ~ 34

Author(s):

Antonio Cano ◽

Camil Castelo-Branco ◽

Juan J Tarı́n

Keyword(s):

Growth Hormone ◽

Growth Factor ◽

Binding Protein ◽

Insulin Like Growth Factor ◽

Growth Hormone Releasing Hormone ◽

Serum Growth Hormone ◽

Releasing Hormone ◽

Factor Binding ◽

Igfbp 3

Download Full-text

Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.80.9.2646 ◽

1995 ◽

Vol 80 (9) ◽

pp. 2646-2652 ◽

Cited By ~ 29

Author(s):

A. Hilding

Keyword(s):

Growth Hormone ◽

Growth Factor ◽

Healthy Subjects ◽

Binding Protein ◽

Diabetic Patients ◽

Insulin Like Growth Factor ◽

Factor Binding ◽

Insulin Dependent ◽

Insulin Dependent Diabetic ◽

Circulating Levels

Download Full-text

Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects.

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jcem.80.9.7545695 ◽

1995 ◽

Vol 80 (9) ◽

pp. 2646-2652

Author(s):

A Hilding ◽

K Brismar ◽

M Degerblad ◽

M Thorén ◽

K Hall

Keyword(s):

Growth Hormone ◽

Growth Factor ◽

Healthy Subjects ◽

Binding Protein ◽

Diabetic Patients ◽

Insulin Like Growth Factor ◽

Factor Binding ◽

Insulin Dependent ◽

Insulin Dependent Diabetic ◽

Circulating Levels

Download Full-text

Measurement of the acid-labile subunit of the insulin-like growth factor binding protein complex in human serum: a comparison of four immunoassays

Journal of Endocrinology ◽

10.1677/joe.0.1650271 ◽

2000 ◽

Vol 165 (2) ◽

pp. 271-279 ◽

Cited By ~ 6

Author(s):

RC Baxter ◽

M Svejkar ◽

MJ Khosravi ◽

GL Bennett ◽

KV Hardman ◽

...

Keyword(s):

Growth Hormone ◽

Growth Factor ◽

Protein Complex ◽

Binding Protein ◽

Serum Marker ◽

Healthy Children ◽

Insulin Like Growth Factor ◽

Factor Binding ◽

Acid Labile Subunit ◽

Acid Labile

The acid-labile subunit (ALS) of the high molecular weight insulin-like growth factor binding protein complex is a liver-derived glycoprotein which is regulated by growth hormone and serves as a serum marker of growth hormone action. We have compared the measurement of ALS by four immunoassay methods (two RIAs, two ELISAs) utilizing various polyclonal and monoclonal antibodies raised against natural or recombinant human ALS, or synthetic ALS peptides. Despite the variety of methodologies and reagents, results obtained by the four methods were highly correlated for 125 sera from various patient groups, and when compared for individual groups of sera from healthy children and adults, growth hormone-deficient children and adults, and subjects with acromegaly. Some weaker correlations among methods were seen when measuring ALS levels in groups of sera from pregnant subjects and subjects with chronic renal failure. An assay using antibodies raised against recombinant ALS yielded lower apparent values than the other methods in patient sera, the discrepancy probably being attributable to a difference in standardization. We conclude that a variety of assay formats and reagents can yield serum ALS values of potential clinical utility.

Download Full-text